Camilla Bathurst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Camilla Bathurst has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Anna Rowe
Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
3 shared publications - Amanda Kirkham
Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
2 shared publications - Ankit Rao
The Cancer Centre, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH
2 shared publications - Christina Yap
Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK
2 shared publications - Daniel Palmer
University of Liverpool and Clatterbridge Cancer Centre, Liverpool, UK
2 shared publications - David H. Adams
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
2 shared publications
Latest Publications
- Open Access
- 7 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Feasibility of a new electronic patient-reported outcome (ePRO) system for an advanced therapy clinical trial in immune-mediated inflammatory disease: the PROmics system (Preprint)
BACKGROUND Advanced therapy medicinal products (ATMPs) are increasingly evaluated in early-phase clinical trials, where understanding patient-reported symptoms, tolerability, and health-related quality of life is critical. Electronic patient-reported outcome (ePRO) systems offer potential advantages over paper-based methods, but evidence on their feasibility and acceptability in ATMP trials remains limited. OBJECTIVE To assess the feasibility and acceptability of the PROmics ePRO system when deployed within a phase II, multi-disease ATMP clinical trial involving patients with immune-mediated inflammatory diseases. METHODS A qualitative interview-based feasibility study was embedded within the POLARISE trial, a multicentre phase II ATMP basket trial investigating ORBCEL-C™ in patients with rheumatoid arthritis, primary sclerosing cholangitis, Crohn’s disease, and lupus nephritis. Semi-structured interviews were conducted with trial participants and research and clinical staff who used the PROmics system. Interviews explored experiences of training, usability, questionnaire burden, real-time alerts, and integration within trial workflows. Transcripts were thematically analysed using the framework method. RESULTS Fourteen participants were interviewed (seven patients and seven staff). Overall, the PROmics system was perceived as acceptable, intuitive, and easy to use by both patients and staff. Automated reminders and real-time alerts were key facilitators of engagement and provided reassurance to patients that their symptoms were actively monitored. However, several feasibility challenges were identified, including technical issues, uncertainty around support pathways, questionnaire burden, and the workload associated with managing alerts. Staff turnover and limitations in clinical dashboard usability and system integration further increased implementation burden. CONCLUSIONS The PROmics ePRO system was acceptable and valued by patients and staff in the context of an ATMP trial, but successful implementation requires careful attention to technical stability, user support, questionnaire scheduling, and alert management within existing trial infrastructure. Addressing these issues is essential to maximise the feasibility, sustainability, and value of digital PROM collection in future ATMP clinical trials. CLINICALTRIAL n/a INTERNATIONAL REGISTERED REPORT RR2-10.1136/bmjopen-2022-063199
- 7 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessFeasibility of a new electronic patient-reported outcome (ePRO) system for an advanced therapy clinical trial in immune-mediated inflammatory disease: the PROmics system (Preprint)
BACKGROUND Advanced therapy medicinal products (ATMPs) are increasingly evaluated in early-phase clinical trials, where understanding patient-reported symptoms, tolerability, and health-related quality of life is critical. Electronic patient-reported outcome (ePRO) systems offer potential advantages over paper-based methods, but evidence on their feasibility and acceptability in ATMP trials remains limited. OBJECTIVE To assess the feasibility and acceptability of the PROmics ePRO system when deployed within a phase II, multi-disease ATMP clinical trial involving patients with immune-mediated inflammatory diseases. METHODS A qualitative interview-based feasibility study was embedded within the POLARISE trial, a multicentre phase II ATMP basket trial investigating ORBCEL-C™ in patients with rheumatoid arthritis, primary sclerosing cholangitis, Crohn’s disease, and lupus nephritis. Semi-structured interviews were conducted with trial participants and research and clinical staff who used the PROmics system. Interviews explored experiences of training, usability, questionnaire burden, real-time alerts, and integration within trial workflows. Transcripts were thematically analysed using the framework method. RESULTS Fourteen participants were interviewed (seven patients and seven staff). Overall, the PROmics system was perceived as acceptable, intuitive, and easy to use by both patients and staff. Automated reminders and real-time alerts were key facilitators of engagement and provided reassurance to patients that their symptoms were actively monitored. However, several feasibility challenges were identified, including technical issues, uncertainty around support pathways, questionnaire burden, and the workload associated with managing alerts. Staff turnover and limitations in clinical dashboard usability and system integration further increased implementation burden. CONCLUSIONS The PROmics ePRO system was acceptable and valued by patients and staff in the context of an ATMP trial, but successful implementation requires careful attention to technical stability, user support, questionnaire scheduling, and alert management within existing trial infrastructure. Addressing these issues is essential to maximise the feasibility, sustainability, and value of digital PROM collection in future ATMP clinical trials. CLINICALTRIAL n/a INTERNATIONAL REGISTERED REPORT RR2-10.1136/bmjopen-2022-063199
- Open Access
- 1 August 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-45
Addition of a dendritic cell vaccine to conditioning cyclophosphamide and chemoembolisation to prolong progression-free survival in patients with hepatocellular carcinoma: the ImmunoTACE RCT
Background: A previous study by our group using dendritic cells pulsed ex vivo with the lysate of the HepG2 cell line showed clinical benefit with evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. This trial set out to investigate the activity of this vaccine in combination with chemoembolisation compared to chemoembolisation alone in patients with intermediate stage hepatocellular carcinoma. All patients also received a conditioning regimen comprising low-dose cyclophosphamide. Objectives: To determine whether the addition of a dendritic cell vaccine to chemoembolisation and preconditioning cyclophosphamide prolongs progression-free survival and warrants further investigation. Design: Multicentre, open-label, randomised Phase II trial. Setting: Three tertiary referral units in the United Kingdom: Queen Elizabeth Hospital, Birmingham; Aintree University Hospital/Clatterbridge Cancer Centre, Liverpool and Queen’s Medical Centre, Nottingham. Participants: Patients > 18 years with intermediate stage hepatocellular carcinoma, performance status 0–2 and Child–Pugh A/B7 liver function. Intervention: Preconditioning cyclophosphamide on Day 1 and Day 29 followed by chemoembolisation on Day 31 (± dendritic cell infusion), followed by further preconditioning cyclophosphamide on Days 60, 90 and 120 (± additional dendritic cell infusions on Days 62, 92 and 122). Main outcome measures: The primary endpoint was progression-free survival time using Response Evaluation Criteria in Solid Tumours v1.1 criteria. Secondary endpoints were progression-free survival time based on modified (m) Response Evaluable Criteria in Solid Tumours criteria, overall survival time, radiological response according to Response Evaluable Criteria in Solid Tumours 1.1 criteria, radiological response based on Modified Response Evaluable Criteria in Solid Tumours criteria, change in the serum alpha-fetoprotein tumour marker, toxicity using Common Terminology Criteria for Adverse Events v4.0 and immune response. Results: Between March 2016 and October 2019, 55 patients were randomised of whom 48 are evaluable (24 in each group). The progression-free survival time using Response Evaluable Criteria in Solid Tumours criteria was 18.6 months in patients treated with chemoembolisation plus preconditioning cyclophosphamide plus dendritic cell infusions (Group 2) compared to 10.4 months in those treated with chemoembolisation plus preconditioning cyclophosphamide alone (Group 1) (hazard ratio 0.43, upper value of one-sided 80% confidence interval 0.57; p = 0.016). Although not statistically powered, the progression-free survival time using Modified Response Evaluable Criteria in Solid Tumours criteria showed a similar magnitude of benefit (18.6 vs 10.8 months: hazard ratio 0.48, 95% confidence interval 0.22 to 1.02). The overall response rate (complete response and partial response) by Response Evaluable Criteria in Solid Tumours was 54% in Group 2 and 29% in Group 1 and the disease control rate (complete response, partial response and stable disease) was 92% in Group 2 and 67% in Group 1. Treatment with dendritic cell vaccination was associated with an enhanced antigen-specific immune response. Treatment was well tolerated with few additional adverse events from the additional dendritic cell infusions. Conclusions: Chemoembolisation plus preconditioning cyclophosphamide plus dendritic cell infusions merit further investigation in a randomised Phase III trial but the trial design will need to take into account the current evolving hepatocellular carcinoma treatment landscape. Limitations: The current dendritic cell manufacturing process limits large-scale use and further validation and automation of the process will be needed prior to testing in a randomised Phase III trial. Future Work: Further testing in a randomised Phase III trial is warranted. Trial registration: This trial is registered as ISRCTN11889464; EudraCT number: 2011-001690-62. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 09/160/24) and is published in full in Efficacy and Mechanism Evaluation; Vol. 12, No. 9. See the NIHR Funding and Awards website for further award information.
- 1 August 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-45
Open AccessAddition of a dendritic cell vaccine to conditioning cyclophosphamide and chemoembolisation to prolong progression-free survival in patients with hepatocellular carcinoma: the ImmunoTACE RCT
Background: A previous study by our group using dendritic cells pulsed ex vivo with the lysate of the HepG2 cell line showed clinical benefit with evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. This trial set out to investigate the activity of this vaccine in combination with chemoembolisation compared to chemoembolisation alone in patients with intermediate stage hepatocellular carcinoma. All patients also received a conditioning regimen comprising low-dose cyclophosphamide. Objectives: To determine whether the addition of a dendritic cell vaccine to chemoembolisation and preconditioning cyclophosphamide prolongs progression-free survival and warrants further investigation. Design: Multicentre, open-label, randomised Phase II trial. Setting: Three tertiary referral units in the United Kingdom: Queen Elizabeth Hospital, Birmingham; Aintree University Hospital/Clatterbridge Cancer Centre, Liverpool and Queen’s Medical Centre, Nottingham. Participants: Patients > 18 years with intermediate stage hepatocellular carcinoma, performance status 0–2 and Child–Pugh A/B7 liver function. Intervention: Preconditioning cyclophosphamide on Day 1 and Day 29 followed by chemoembolisation on Day 31 (± dendritic cell infusion), followed by further preconditioning cyclophosphamide on Days 60, 90 and 120 (± additional dendritic cell infusions on Days 62, 92 and 122). Main outcome measures: The primary endpoint was progression-free survival time using Response Evaluation Criteria in Solid Tumours v1.1 criteria. Secondary endpoints were progression-free survival time based on modified (m) Response Evaluable Criteria in Solid Tumours criteria, overall survival time, radiological response according to Response Evaluable Criteria in Solid Tumours 1.1 criteria, radiological response based on Modified Response Evaluable Criteria in Solid Tumours criteria, change in the serum alpha-fetoprotein tumour marker, toxicity using Common Terminology Criteria for Adverse Events v4.0 and immune response. Results: Between March 2016 and October 2019, 55 patients were randomised of whom 48 are evaluable (24 in each group). The progression-free survival time using Response Evaluable Criteria in Solid Tumours criteria was 18.6 months in patients treated with chemoembolisation plus preconditioning cyclophosphamide plus dendritic cell infusions (Group 2) compared to 10.4 months in those treated with chemoembolisation plus preconditioning cyclophosphamide alone (Group 1) (hazard ratio 0.43, upper value of one-sided 80% confidence interval 0.57; p = 0.016). Although not statistically powered, the progression-free survival time using Modified Response Evaluable Criteria in Solid Tumours criteria showed a similar magnitude of benefit (18.6 vs 10.8 months: hazard ratio 0.48, 95% confidence interval 0.22 to 1.02). The overall response rate (complete response and partial response) by Response Evaluable Criteria in Solid Tumours was 54% in Group 2 and 29% in Group 1 and the disease control rate (complete response, partial response and stable disease) was 92% in Group 2 and 67% in Group 1. Treatment with dendritic cell vaccination was associated with an enhanced antigen-specific immune response. Treatment was well tolerated with few additional adverse events from the additional dendritic cell infusions. Conclusions: Chemoembolisation plus preconditioning cyclophosphamide plus dendritic cell infusions merit further investigation in a randomised Phase III trial but the trial design will need to take into account the current evolving hepatocellular carcinoma treatment landscape. Limitations: The current dendritic cell manufacturing process limits large-scale use and further validation and automation of the process will be needed prior to testing in a randomised Phase III trial. Future Work: Further testing in a randomised Phase III trial is warranted. Trial registration: This trial is registered as ISRCTN11889464; EudraCT number: 2011-001690-62. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 09/160/24) and is published in full in Efficacy and Mechanism Evaluation; Vol. 12, No. 9. See the NIHR Funding and Awards website for further award information.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (16) , OF1-OF12
Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial
Purpose: A previous study by our group using dendritic cells (DC) pulsed ex vivo with the lysate of the HepG2 cell line showed evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. The ImmunoTACE trial evaluated the preliminary activity of this vaccine in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma. Patients and Methods: A randomized phase II trial was conducted in three tertiary referral centers in the United Kingdom. Eligible patients were randomly assigned in a 1:1 ratio to TACE + preconditioning cyclophosphamide or to TACE + preconditioning cyclophosphamide + DC infusions. The primary endpoint was progression-free survival time using RECIST v1.1 criteria. Additional endpoints included safety and immune responses. Results: Between March 2016 and October 2019, 55 patients were randomized, of whom 48 were evaluable (24 in each group). The median progression-free survival time using RECIST criteria was 18.6 months in patients treated with chemoembolization + preconditioning cyclophosphamide + DC infusions compared with 10.4 months in those treated with chemoembolization + preconditioning cyclophosphamide alone (HR = 0.43; upper value of one-sided 80% confidence interval, 0.57; P = 0.016). The addition of DC infusions did not significantly increase the incidence or severity of adverse events. An enhanced antigen (α-fetoprotein)-specific immune response was observed in patients treated with DC vaccination. Conclusions: The addition of DC infusions to TACE and preconditioning cyclophosphamide has shown promising preliminary activity and merits further investigation in a larger randomized trial.
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (16) , OF1-OF12
Open AccessAddition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial
Purpose: A previous study by our group using dendritic cells (DC) pulsed ex vivo with the lysate of the HepG2 cell line showed evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. The ImmunoTACE trial evaluated the preliminary activity of this vaccine in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma. Patients and Methods: A randomized phase II trial was conducted in three tertiary referral centers in the United Kingdom. Eligible patients were randomly assigned in a 1:1 ratio to TACE + preconditioning cyclophosphamide or to TACE + preconditioning cyclophosphamide + DC infusions. The primary endpoint was progression-free survival time using RECIST v1.1 criteria. Additional endpoints included safety and immune responses. Results: Between March 2016 and October 2019, 55 patients were randomized, of whom 48 were evaluable (24 in each group). The median progression-free survival time using RECIST criteria was 18.6 months in patients treated with chemoembolization + preconditioning cyclophosphamide + DC infusions compared with 10.4 months in those treated with chemoembolization + preconditioning cyclophosphamide alone (HR = 0.43; upper value of one-sided 80% confidence interval, 0.57; P = 0.016). The addition of DC infusions did not significantly increase the incidence or severity of adverse events. An enhanced antigen (α-fetoprotein)-specific immune response was observed in patients treated with DC vaccination. Conclusions: The addition of DC infusions to TACE and preconditioning cyclophosphamide has shown promising preliminary activity and merits further investigation in a larger randomized trial.
- Open Access
- 26 August 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (9) , 837
Metabolomic Biomarker Candidates for Skeletal Muscle Loss in the Collagen-Induced Arthritis (CIA) Model
There is no consensus for diagnosis or treatment of RA muscle loss. We aimed to investigate metabolites in arthritic mice urine as biomarkers of muscle loss. DBA1/J mice comprised collagen-induced arthritis (CIA) and control (CO) groups. Urine samples were collected at 0, 18, 35, 45, 55, and 65 days of disease and subjected to nuclear magnetic resonance spectroscopy. Metabolites were identified using Chenomx and Birmingham Metabolite libraries. The statistical model used principal component analysis, partial least-squares discriminant analysis, and partial least-squares regression analysis. Linear regression and Fisher’s exact test via the MetaboAnalyst website were performed (VIP-score). Nearly 100 identified metabolites had CIA vs. CO and disease time-dependent differences (p < 0.05). Twenty-eight metabolites were muscle-associated: carnosine (VIPs 2.8 × 102) and succinyl acetone (VIPs 1.0 × 10) showed high importance in CIA vs. CO models at day 65; CIA pair analysis showed histidine (VIPs 1.2 × 102) days 55 vs. 65, histamine (VIPs 1.1 × 102) days 55 vs. 65, and L-methionine (VIPs 1.1 × 102) days 0 vs. 18. Carnosine was fatigue- (0.039) related, creatine was food intake- (−0.177) and body weight- (−0.039) related, and both metabolites were clinical score- (0.093; 0.050) and paw edema- (0.125; 0.026) related. Therefore, muscle metabolic alterations were detected in arthritic mice urine, enabling further validation in RA patient’s urine, targeting prognosis, diagnosis, and monitoring of RA-mediated muscle loss.
- 26 August 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (9) , 837
Open AccessMetabolomic Biomarker Candidates for Skeletal Muscle Loss in the Collagen-Induced Arthritis (CIA) Model
There is no consensus for diagnosis or treatment of RA muscle loss. We aimed to investigate metabolites in arthritic mice urine as biomarkers of muscle loss. DBA1/J mice comprised collagen-induced arthritis (CIA) and control (CO) groups. Urine samples were collected at 0, 18, 35, 45, 55, and 65 days of disease and subjected to nuclear magnetic resonance spectroscopy. Metabolites were identified using Chenomx and Birmingham Metabolite libraries. The statistical model used principal component analysis, partial least-squares discriminant analysis, and partial least-squares regression analysis. Linear regression and Fisher’s exact test via the MetaboAnalyst website were performed (VIP-score). Nearly 100 identified metabolites had CIA vs. CO and disease time-dependent differences (p < 0.05). Twenty-eight metabolites were muscle-associated: carnosine (VIPs 2.8 × 102) and succinyl acetone (VIPs 1.0 × 10) showed high importance in CIA vs. CO models at day 65; CIA pair analysis showed histidine (VIPs 1.2 × 102) days 55 vs. 65, histamine (VIPs 1.1 × 102) days 55 vs. 65, and L-methionine (VIPs 1.1 × 102) days 0 vs. 18. Carnosine was fatigue- (0.039) related, creatine was food intake- (−0.177) and body weight- (−0.039) related, and both metabolites were clinical score- (0.093; 0.050) and paw edema- (0.125; 0.026) related. Therefore, muscle metabolic alterations were detected in arthritic mice urine, enabling further validation in RA patient’s urine, targeting prognosis, diagnosis, and monitoring of RA-mediated muscle loss.